Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

14.52USD
2:51pm EDT
Change (% chg)

$-0.22 (-1.46%)
Prev Close
$14.74
Open
$14.80
Day's High
$14.93
Day's Low
$14.40
Volume
2,754,260
Avg. Vol
3,434,080
52-wk High
$44.41
52-wk Low
$14.30

Select another date:

Tue, Oct 17 2017

BRIEF-Teva announces submission of biologics license application for Fremanezumab to U.S. FDA

* Teva announces submission of biologics license application for Fremanezumab to the U.S. FDA

BRIEF-BioDelivery sciences announces patent litigation settlement agreement with Teva

* BioDelivery Sciences announces patent litigation settlement agreement with Teva

Teva's Copaxone faces generic competition in Europe after U.S. hit

LONDON Teva's blockbuster multiple sclerosis treatment Copaxone will face additional generic competition in Europe, just two days after Mylan NV won U.S. approval to sell cheaper versions of the medicine in the world's largest market.

UPDATE 1-Teva's Copaxone faces generic competition in Europe after U.S. hit

LONDON, Oct 5 Teva's blockbuster multiple sclerosis treatment Copaxone will face additional generic competition in Europe, just two days after Mylan NV won U.S. approval to sell cheaper versions of the medicine in the world's largest market.

Teva's Copaxone faces more generic competition in Europe

LONDON, Oct 5 Teva's blockbuster multiple sclerosis treatment Copaxone faces more generic competition in Europe, just two days after regulators approved cut-price copies of the medicine in the United States.

Mylan surges, Teva slumps after FDA approves Copaxone copy

Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while Teva shares plunged.

UPDATE 4-Mylan surges, Teva slumps after FDA approves Copaxone copy

Oct 4 Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while Teva shares plunged.

BRIEF-Teva comments on anticipated at-risk U.S. Launch of generic Glatiramer Acetate

* Teva comments on anticipated at-risk U.S. Launch of generic Glatiramer Acetate 40mg/ml and launch of generic Glatiramer Acetate 20mg/ml

Mylan surges as its generic of Teva's Copaxone gets FDA nod

Oct 4 Shares of Mylan NV jumped about 17 percent in premarket trading on Wednesday after the U.S. Food and Drug Administration approved the drugmaker's copycat version of Teva Pharmaceutical Industries Ltd's blockbuster multiple sclerosis drug.

BRIEF-Teva Pharmaceutical Industries says Dan Suesskind appointed to co's board

* Teva Pharmaceutical Industries Ltd says Dan Suesskind appointed to co's board of directors Source text: (http://bit.ly/2wfjwNR) Further company coverage:

Select another date: